Immune Checkpoint Inhibitors: all 7,814 studies that test it

Page 21 of 79. Open to participants first (2,629), then studies with results posted, then the rest; newest registration first within each.

• A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849RecruitingNCT05761223Phase 1/2
• Tislelizumab Combined APF Chemotherapy in the Treatment of Locally Advanced Head and Neck TumorsRecruitingNCT05758389Phase 2
• Prolgolimab Monotherapy or in Combination With Bendamustine for r/r Classical Hodgkin LymphomaRecruitingNCT05757466Phase 2
• Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant HistologyRecruitingNCT05756569Phase 2
• Adebrelimab Combined With Fuzuloparib in the Treatment of Patients With Recurrent Platinum-resistant Ovarian Cancer.RecruitingNCT05753826Phase 2
• Preoperative Short-course Radiation Followed by Envafolimab Plus CAPEOX for MSS Locally Advanced Rectal AdenocarcinomaRecruitingNCT05752136Phase 3
• Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or LymphomasRecruitingNCT05751798Phase 1/2
• Tislelizumab Combined With Chemotherapy in the Cross-line Treatment of First-line Resistant Advanced Gastric CancerNot yet recruitingNCT05751265Phase 2
• First-line Trastuzumab, Gemcitabine, Cisplatin and Nivolumab in Advanced HER2- Positive Biliary Tract Cancer: a Multicenter, Open-label, Single-arm Phase Ib/II Trial (HERBOT)RecruitingNCT05749900Phase 1/2
• FUSCC Refractory TNBC Platform Study (FUTURE2.0)RecruitingNCT05749588Phase 2
• A Single-arm, Open-label, Clinical Trial of Surufatinib/Serplulimab/Platinum/Etoposide in Neuroendocrine Carcinoma.RecruitingNCT05747729Phase 1/2
• A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid TumorsRecruitingNCT05746897Phase 1
• Surufatinib Combined With Tislelizumab in the Second-line and Further Treatment of Triple-negative Breast CancerNot yet recruitingNCT05746728Phase 1/2
• Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine TumorsRecruitingNCT05746208Phase 2
• First Line Pembrolizumab, Plinabulin Plus Etoposide and Platinum (EP) for ES-SCLCRecruitingNCT05745350Phase 2
• Intraperitoneal Immune Checkpoint Inhibitor for Malignant AscitesEnrolling by invitationNCT05745233Not applicable
• Immunotherapy With CCRT Followed by Surgery for Locally Advanced ESCC PatientsRecruitingNCT05743504Phase 1/2
• IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)RecruitingNCT05742607Phase 2
• Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast CancerRecruitingNCT05741164Phase 2
• Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell CarcinomaRecruitingNCT05738694Phase 3
• PD-1 Antibody Combined With mXELIRI Versus mXELIRI in the Second-line Setting for ESCCRecruitingNCT05737563Phase 3
• The Efficacy and Safety of PD-1/PD-L1 Inhibitors Combined With Centipeda Minima (CM) in Lung CancerRecruitingNCT05735028Phase 1
• Neoadjuvant Pembrolizumab and Lenvatinib for Renal Cell CarcinomaRecruitingNCT05733715Early Phase 1
• Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)RecruitingNCT05733689Phase 1
• SBRT Combined With AK104 to Treatment Relapsed or Metastatic ESCCNot yet recruitingNCT05732662Phase 2
• Immunotherapy in Patients With Early dMMR Rectal CancerRecruitingNCT05732389Phase 2
• Serplulimab Combined With CAPEOX + Celecoxib as Neoadjuvant Treatment for Locally Advanced Rectal CancerRecruitingNCT05731726Phase 2
• Perioperative Chemotherapy Plus Toripalimab for dMMR Locally Advanced Gastric or Esophagogastric Junction AdenocarcinomaRecruitingNCT05729646Phase 2
• Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.RecruitingNCT05727904Phase 3
• Neoadjuvant Nivolumab, Docetaxel, Cisplatin Therapy Followed by Surgery and Radiation Therapy for Resectable High Grade Salivary Gland CarcinomaRecruitingNCT05727410Phase 2
• Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCCRecruitingNCT05726370Phase 2
• Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal CancerRecruitingNCT05725200Phase 2
• KD6001 in Combination With Anti-PD-1 Antibody in Patients With Advanced MelanomaRecruitingNCT05723432Phase 1/2
• Surufatinib and Envafolimab as Second or More-line Therapy in Advanced Soft Tissue Sarcoma PatientsNot yet recruitingNCT05722977Phase 2
• DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening ProtocolRecruitingNCT05722886Phase 2/3
• Efficacy and Safety of Fruquintinib in Combination With PD-1 Inhibitors as First-line Maintenance Therapy for Advanced HER-2 Negative Gastric Cancer: a Single-arm, Prospective, Exploratory Clinical StudyRecruitingNCT05721651Phase 2
• Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBCRecruitingNCT05720260Phase 2
• Piamprilizumab (AK105) Combined With Radiotherapy for Neoadjuvant Treatment of Soft Tissue SarcomaRecruitingNCT05718778Not applicable
• TQB2450 Injection Combined With Chemotherapy Followed by Sequential Combination With Anlotinib Hydrochloride Capsule for First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer.Not yet recruitingNCT05718167Phase 3
• Efficacy and Safety Study of First-line Treatment With SG001 Plus Chemotherapy ± Bevacizumab Versus Placebo Plus Chemotherapy ±Bevacizumab for Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS≥1)Not yet recruitingNCT05715840Phase 3
• Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain MetastasesRecruitingNCT05704647Phase 2
• FASTing-like Approach and Maintenance IMMunotherapy in ES-SCLC Patients Not Progressing on Chemoimmunotherapy InductionNot yet recruitingNCT05703997Phase 2
• Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC PatientsRecruitingNCT05703971Phase 1/2
• Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaRecruitingNCT05702229Phase 2
• Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)RecruitingNCT05700721Phase 2
• Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell LymphomaNot yet recruitingNCT05700448Phase 3
• Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 Vs Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric CancerRecruitingNCT05699655Phase 2/3
• Quick Start Durvalumab Following Chemoradiation for Stage III Nonsmall Cell Lung CancerRecruitingNCT05696782Phase 2
• Maintenance Pembrolizumab at Usual or Low doSE in Non-squamous Lung Cancer: a Non-inferiority StudyRecruitingNCT05692999Phase 3
• A Phase I Study of BC3402 as a Single Agent in Patients With MDS and CMMLRecruitingNCT05690425Phase 1
• Study of AK119 Combined With AK112 in Patients With Advanced Solid TumorsRecruitingNCT05689853Phase 1/2
• A Study of MRG003 in the Treatment of Patients With EGFR-positive Advanced or Metastatic Solid TumorsRecruitingNCT05688605Phase 1/2
• Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic AdenocarcinomaRecruitingNCT05688215Phase 1/2
• Tislelizumab in Combination With Pre-operative CRT Versus SOC for Locally Advanced G/GEJ AdenocarcinomaRecruitingNCT05687357Phase 2
• Tislelizumab With Anlotinib and Chemotherapy for Second-line Treatment of Pancreatic CancerRecruitingNCT05681390Phase 2
• Pazopanib With or Without Pembrolizumab for Metastatic Soft Tissue SarcomaRecruitingNCT05679921Phase 2
• A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and NivolumabRecruitingNCT05675410Phase 3
• Durvalumab Combined With GemCis Neoadjuvant Therapy of Resectable Intrahepatic Cholangiocarcinoma With High Recurrence RiskRecruitingNCT05672537Phase 2
• Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2 Expression Gastric CancerRecruitingNCT05671822Phase 2
• Study of Healthy Donor FMT (hdFMT) and Pembrolizumab in Relapsed/Refractory (R/R) PD-L1 Positive NSCLCRecruitingNCT05669846Phase 2
• A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor MalignanciesRecruitingNCT05669430Phase 1/2
• A Phase III Trial of Anus-preservation in Low Rectal Adenocarcinoma Based on MMR/MSI StatusRecruitingNCT05669092Phase 3
• Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)RecruitingNCT05665361Phase 1/2
• Renal Retention in High Grade Upper Tract Urothelial CancerRecruitingNCT05656235Phase 2
• Y-90 With Durvalumab/Gem/Cis in Intrahepatic CholangioRecruitingNCT05655949Phase 2
• Safe Stop Ipilimumab-nivolumab (IPI-NIVO) TrialRecruitingNCT05652673Not applicable
• Propranolol in Combination With Pembrolizumab and Standard Chemotherapy for the Treatment of Unresectable Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction AdenocarcinomaRecruitingNCT05651594Phase 2
• A Study of B1962, a PD-L1/VEGF Bispecific Antibody Fusion Protein, for Advanced Solid TumorsNot yet recruitingNCT05650385Phase 1
• HIPEC Combined With Sintilimab for Gastric Cancer With Peritoneal MetastasisNot yet recruitingNCT05648487Phase 2
• First-Line Treatment for Advanced Non-squamous Non-Small-Cell Lung Cancer With Negative Driver Gene: a Single-center, Single-Arm TrialRecruitingNCT05648071Phase 3
• Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid MesotheliomaRecruitingNCT05647265Phase 2
• A Study Evaluating Cadonilimab Injection in Combination With Regorafenib for the Treatment of Biliary Systemic TumoursRecruitingNCT05644392Phase 1
• A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of HLX208+HLX10 in NSCLC With BRAF V600E MutationRecruitingNCT05641493Phase 1/2
• Durvalumab Combined With Chemotherapy Neoadjuvant Therapy of Biliary Tract CancerRecruitingNCT05640791Phase 2
• The First-line Treatment of RCLM With RAS Mutation Was Local Short-course Radiotherapy (SCRT) + PD-1+ Standard TherapyNot yet recruitingNCT05640726Phase 2
• Sintilimab in Combination With Bevacizumab and Temozolomide in Recurrent Glioblastoma (GBM) PatientsRecruitingNCT05638451Phase 2
• Carrelizumab Combined With Chemotherapy for Adjuvant Therapy of Esophageal Squamous Cell CarcinomaRecruitingNCT05637268Phase 2
• A Feasibility Window Study of Pembrolizumab Prior to Second Evacuation for Post-molar Gestational Trophoblastic NeoplasiaRecruitingNCT05635344Phase 2
• Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint InhibitorsRecruitingNCT05629546Phase 1
• Modulation Therapy for Locally Advanced NPC Based on Plasma EBV DNA Level Post-ICTRecruitingNCT05628922Phase 2
• The Combination of Hypofractionated Radiotherapy and Immunotherapy in Locally Recurrent Rectal CancerRecruitingNCT05628038Phase 2
• Camrelizumab Combined With Chemoradiotherapy in Advanced Esophageal Cancer.RecruitingNCT05624099Phase 2
• A Study of GNC-038 Injection in Patients With Relapsed or Refractory Non-Hodgkin's LymphomaRecruitingNCT05623982Phase 1/2
• Pembrolizumab and Olaparib Treatment of Extensive Small Cell Lung Cancer (ES-SCLC)RecruitingNCT05623319Phase 2
• Sugemalimab as Consolidation Therapy in Patients With LS-SCLC Following cCRT or sCRTRecruitingNCT05623267Phase 2/3
• Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-riskRecruitingNCT05620771Phase 2
• Ph2 Study of Savolitinib and Durvalumab (MEDI4736) Combination in Advanced MET Amplified Gastric Cancer(VIKTORY-2)RecruitingNCT05620628Phase 2
• Sintilimab Combined With Bevacizumab and Liver Protective Support Therapy in Unresectable Hepatocellular CarcinomaRecruitingNCT05616390Phase 2
• A Pilot Phase II Study of Maintenance Cabozantinib Plus Pembrolizumab for Patients With Metastatic Squamous Non-Small Cell Lung Cancer (sqNSCLC)RecruitingNCT05613413Phase 2
• Neoadjuvant of Tislelizumab Combined With Chemotherapy Followed by Surgery in Unresectable Stage Ⅲ NSCLCRecruitingNCT05611879Phase 2
• Clinical Efficacy in Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different ImmunotypesNot yet recruitingNCT05610332Phase 3
• Efficacy and Safety of Caldonirimab Plus Nimotuzumab for Recurrent or Metastatic Cervical CancerRecruitingNCT05606263Phase 2
• PD-1 Antibody in Addition to BACE in Patients With NSCLC: A Randomised Controlled TrialRecruitingNCT05605613Phase 2/3
• Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial CarcinomaRecruitingNCT05603910Phase 1
• Chemotherapy and Sequential Immunotherapy for Locally Advanced Urothelial CancerRecruitingNCT05600127Phase 2
• Nivolumab/Ipilimumab and Chemotherapy Combination in Advanced NSCLC Patients With HIV, HBV, HCV and Long Covid SyndromeNot yet recruitingNCT05597800Phase 2
• Patient-reported Outcomes in Preoperative Immunochemotherapy/Radiotherapy-treated Esophageal Cancer PatientsRecruitingNCT05596890Phase 2
• Radiotherapy With Tislelizumab in Patients With Recurrent Head & Neck CancerRecruitingNCT05595590Phase 2
• AK104 Plus Concurrent Chemoradiation Therapy in Esophageal Squamous Cell CarcinomaNot yet recruitingNCT05594914Phase 2
• A Biomarker Study for Predicting the Efficacy of Neoadjuvant Sintilimab Plus SOX for Gastric Adenocarcinoma.Not yet recruitingNCT05594381Phase 2

← Immune Checkpoint Inhibitors overview